How to start ai startup?

Start with a clinical problem, not a model

Most first-time founders begin with “we can build an AI that detects X.” In medtech, the winning sequence is the opposite: pick a painful, frequent, expensive workflow problem, then decide whether AI is the simplest solution that can be validated and sold.

A useful filter is: frequency × severity × ability to act. If your AI flags something but no one can act on it (no protocol, no staffing, no time), adoption stalls.

• Frequency: How often does the decision occur (per day/per shift/per patient)?
• Severity: Does it change outcomes, reduce harm, or prevent costly downstream events?
• Ability to act: Is there a clear next step (order set, consult, escalation, discharge decision)?

Translate the problem into a one-line “job to be done” statement: “Help [user] decide [decision] in [context] so they can [outcome].” Example: “Help ED clinicians decide which chest pain patients need admission in the first 30 minutes so they can reduce unnecessary admissions without missing MI.”

Define your wedge: user, workflow, and buyer (they’re often different)

In hospitals, the user (clinician), economic buyer (department head, service line leader, CFO), and technical buyer (IT/security) are rarely the same person. Your wedge is the smallest product that creates measurable value for a specific workflow and has a believable path through procurement.

Map the “three buyers” early

• User: Who clicks, reads, or acts on the output? What do they do today?
• Economic buyer: Who owns the budget (radiology, cardiology, quality, population health)?
• Technical buyer: Who approves integration, security review, and deployment (IT, infosec, clinical engineering)?

Then decide your integration burden. In medtech AI, distribution is often harder than modeling. A product that requires deep EHR integration (HL7/FHIR, SMART on FHIR, PACS/RIS) may be valuable but slows pilots. Many early teams start with a narrower integration (e.g., a radiology workflow plug-in or a standalone triage dashboard) and expand once value is proven.

Be explicit about what you are selling: decision support (recommendations), automation (reducing manual work), or risk stratification (prioritization). Each implies different evidence, liability posture, and FDA considerations.

Regulatory strategy: decide if you’re SaMD and pick a pathway

In medtech, “AI startup” often means Software as a Medical Device (SaMD): software intended for medical purposes that performs those purposes without being part of a hardware medical device. If your product influences diagnosis, treatment, or triage, assume you may be regulated and design accordingly.

Use an “intended use” statement as your North Star

Your intended use (what the product is for, who uses it, and in what setting) drives everything: risk classification, evidence, labeling, and claims you can make in sales.

Common FDA pathways (high level)

• 510(k): You show your device is substantially equivalent to a legally marketed predicate. Often the fastest if a close predicate exists.
• De Novo: For novel, low-to-moderate risk devices without a predicate. Creates a new classification that others can later reference.
• PMA: For higher-risk devices; typically requires more extensive clinical evidence.

Don’t guess your pathway from blog posts. Instead, do a lightweight regulatory landscape scan: identify similar cleared/authorized products, read their public summaries/labeling, and compare intended use and risk. If you’re early, a short consult with a regulatory expert can prevent months of building the wrong thing.

Also decide how you will handle model updates. “Continuous learning” sounds great, but regulated updates require controls. Many teams start with a locked model and a defined update process.

Data and evidence: build a proof package, not just a model

In medtech AI, performance metrics alone don’t win. Hospitals and regulators care about generalizability (works across sites), clinical utility (changes decisions), and safety (doesn’t create new harm). Your goal is an evidence package that supports regulatory, clinical, and commercial conversations.

Plan your data access like a product requirement

• Source: Retrospective EHR/PACS data, prospective data collection, or a mix.
• Rights: Who can use it, for what purpose, and can you commercialize learnings?
• Quality: Label reliability, missingness, site-specific quirks, and drift over time.

If you need patient data from a hospital, expect governance steps. You may need an IRB approval (Institutional Review Board) for research use, plus a data use agreement. Timelines vary widely, so design a plan that can start with smaller, faster datasets while the larger partnership moves.

Evidence ladder (a practical sequence)

1. Analytical validation: Does the model measure/predict what it claims on held-out data? Include subgroup checks and failure modes.
2. Clinical validation: Does it perform in the intended setting (often multi-site)?
3. Clinical utility: Does it improve workflow or outcomes (or reduce cost) when used by real clinicians?
4. Health economics: Can you quantify ROI for the buyer (time saved, avoided admissions, reduced readmissions, fewer complications)?

Design your MVP to produce evidence as a byproduct. Example: if your product is a triage tool, log time-to-decision, override rates, and downstream outcomes. Those become your pilot readout and sales assets.

Commercialization: reimbursement, procurement, and a believable ROI story

Medtech AI dies in the gap between “works in a notebook” and “gets bought.” You need a commercialization plan that matches how hospitals pay for things.

Pick a payment model that matches your buyer

• Per site / annual license: Common for hospital software; easier budgeting, but you must justify ROI.
• Per study / per use: Sometimes fits radiology/pathology workflows; requires clean measurement and billing alignment.
• Shared savings: Attractive in theory, hard in practice due to attribution and contracting complexity.

Reimbursement basics (don’t skip this)

If your value depends on getting paid per use, you must understand CPT codes (billing codes used in the US). Some AI products are sold as operational tools (no direct reimbursement), while others align with billable services. Whether a new CPT code exists, or whether your product supports an existing billable workflow, can change your go-to-market.

Even if you don’t bill directly, reimbursement still matters because it shapes hospital incentives. A tool that reduces length of stay or prevents penalties may sell through quality/value-based care budgets; a tool that increases throughput may sell through service line leadership.

Procurement reality: sell the pilot, then the rollout

Hospital procurement typically requires security review, legal, compliance, and stakeholder alignment. Your early goal is a paid pilot (even modest) with clear success metrics and a defined path to enterprise rollout.

Define pilot success in numbers before you start. Examples:

• Reduce time-to-interpretation by X minutes (baseline measured during pilot).
• Increase guideline adherence by X% (measured against pre-pilot baseline).
• Reduce unnecessary imaging/orders by X% without increasing adverse events.

Avoid vague pilots like “let’s try it and see.” Those rarely convert to contracts.

What to do next

1. Write a one-paragraph intended use + claims document (who, what decision, setting, output) and list what you will not claim in v1.
2. Run 15 problem interviews: 10 users + 3 economic buyers + 2 IT/security stakeholders; summarize the workflow, current tools, and buying process.
3. Do a regulatory landscape scan of similar products and draft your likely pathway (510(k), De Novo, or PMA) with assumptions and open questions.
4. Design a pilot with 3 measurable endpoints (clinical, operational, economic) and a data collection plan that can support future validation.
5. Build a simple ROI model (inputs, assumptions, sensitivity) to support pricing and procurement conversations.

Helpful next steps on StartupLaby: /basics_form, /launchpad, /Competitor_study, /finances.